Callan Family Office LLC Acquires 4,146 Shares of Thermo Fisher Scientific Inc. $TMO

Callan Family Office LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 34.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,033 shares of the medical research company's stock after purchasing an additional 4,146 shares during the quarter. Callan Family Office LLC's holdings in Thermo Fisher Scientific were worth $6,501,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. CBIZ Investment Advisory Services LLC raised its holdings in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth $31,000. DiNuzzo Private Wealth Inc. raised its holdings in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after acquiring an additional 61 shares during the period. Finally, HighMark Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock worth $31,000 after acquiring an additional 45 shares during the period. Institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on TMO. William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, October 4th. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a report on Thursday, October 2nd. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a report on Thursday. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $593.43.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last ninety days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $534.92 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm's 50-day simple moving average is $487.44 and its 200-day simple moving average is $448.31. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The firm has a market cap of $201.99 billion, a P/E ratio of 30.94, a price-to-earnings-growth ratio of 2.91 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.